Your provider should also review your complete medical history, including any history of pancreatitis, gallbladder disease, thyroid disease (particularly medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2), diabetic retinopathy, kidney disease, or gastrointestinal disorders
BPC-157: 250 to 300 mcg subcutaneously twice daily near the affected level
Who Benefits Most from Microdose GLP-1 Therapy
Related Reading Genetic Testing 101 What You Need To Know Before Getting Tested What Genetic Factors Determine How Much Sleep You Need Each Night What Determines If You Are A Morning Person Or A Night Owl Can A Genetic Test Show If I Need More Selenium For Thyroid Health Pricing and availability current as of July 2026
GHK-Cus gene modulation capacity was documented in a landmark microarray analysis by Pickart et al., identifying 4,000+ gene targets including VEGF upregulation (angiogenesis), SOD2 upregulation (oxidative defense), and downregulation of pro-inflammatory cytokine genes including TNF- and IL-6
Sorafenib, sulfasalazine, statins, and artemisinins have shown efficacy as monotherapy or combination therapy in treating multiple malignancies
